IL6 and congenital rubella syndrome: Siltuximab – IL-6 inhibitor, pre-clinical rationale without significant clinical demonstration of efficacy. Note that tocilizumab (IL-6R inhibitor) should only be used for concomitant CRS as inhibition of the receptor causes transient increases in free IL-6 which may exacerbate ICANS (65, 97, 104)